To check whether the pharmacological efficacy of Cc-ME can be proved by oral administration in vivo and whether Cc-ME can reduce both LPS-dependent and LPS–independent inflammatory disorders, we employed LPS-triggered peritonitis and HCl/EtOH-induced gastritis conditions, as reported previously [33, 35]. This evidence concerns the gene CXCR1 and peritonitis.